Nicotine as an Antiepileptic Agent in ADNFLE: An N-of-One Study
Version of Record online: 12 AUG 2003
Volume 44, Issue 9, pages 1238–1240, September 2003
How to Cite
Willoughby, J. O., Pope, K. J. and Eaton, V. (2003), Nicotine as an Antiepileptic Agent in ADNFLE: An N-of-One Study. Epilepsia, 44: 1238–1240. doi: 10.1046/j.1528-1157.2003.58102.x-i1
- Issue online: 12 AUG 2003
- Version of Record online: 12 AUG 2003
- Accepted May 6, 2003.
- Autosomal dominant nocturnal frontal lobe epilepsy
Summary: Purpose: To test nicotine patch treatment for a patient with a defined mutation for autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) whose seizures were refractory to standard antiepileptic therapy.
Methods: Open and double-blind trials of nicotine patches in an “n-of-one” study. The double-blind trial comprised periods during which either placebo or nicotine patches were each used for three periods of 2 weeks, randomized in a double-blind manner.
Results: In an open study, nicotine patches reduced seizures from 1.65 ± 2.36 to 0.01 ± 0.0 seizures per day (p < 0.0001). In a double-blinded placebo-controlled phase, the average frequency of seizures on nicotine versus placebo was 0 ± 0 versus 0.56 ± 1.14 seizures per day (p < 0.0001).
Conclusions: Nicotine patches may be of benefit to some individuals with ADNFLE.